However, it may be more practical to target the melatonergic pathway in other cells in the tumor microenvironment, such as natural killer cells and/or dendritic cells, likely involving antagonism of the AhR and probably other targets identified by future research in this crucial area of core physiological function. Here, AHR is linked to neoplasm.